Five things for pharma marketers to know: Wednesday, October 28, 2015
Walgreens buys Rite Aid in $9.4 billion deal; Arena fires a third of its workforce and discontinues Belviq clinical trials; FDA approves Amgen melanoma immunotherapy
View ArticleFive things for pharma marketers to know: Monday, November 16, 2015
PBMs crack down on specialty pharmacies; Merck's cholesterol drug soldiers on; rare-disease drug nabs approval
View ArticleFive things for pharma marketers to know: Tuesday, November 24, 2015
Opdivo receives another indication; increasing generic prescriptions may boost patient adherence; hep.-C drugs should be prescribed during earlier stages of disease
View ArticleFive things for pharma marketers to know: Wednesday, November 25, 2015
FDA advisers vote against BioMarin's Duchenne drug; the FDA approves Lilly's lung-cancer drug; criticism mounts for Pfizer's proposed deal with Allergan
View ArticleFive things for pharma marketers to know: Thursday, December 17, 2015
The FDA approves Lilly's Lantus follow-on biologic; AstraZeneca buys majority stake in Acerta Pharma; Shkreli arrested on securities fraud charges
View ArticleFive things for pharma marketers to know: Tuesday, December 29, 2015
Generic-drug approval backlog criticized; KaloBios board members step down; Sovaldi costs as little as $4 in India
View ArticleFive things for pharma marketers to know: Monday, January 4, 2016
The FDA approved 45 new drugs in 2015; Baxalta signs immuno-oncology deal; pharma M&A activity may slow this year
View ArticleFive things for pharma marketers to know: Friday, January 15, 2016
The FDA declines to approve two drugs for Duchenne muscular dystrophy; government watchdog questions FDA's post-market drug tracking; WebMD denies acquisition talks
View ArticleSpeeding up FDA Approvals Calls for Pause
The idea that 30 days is enough time for the FDA to evaluate anything is, of course, quite silly. But Sen. Cruz takes it one step further.
View ArticleFive things for pharma marketers to know: Wednesday, February 3, 2016
Seven potential blockbusters set to launch in 2016; Amarin case may lead to 'misleading' marketing; Valeant, Turing raised prices to meet preset targets
View Article
